Middle East Preimplantation Genetic Testing Market (2025-2030)
The Middle East Preimplantation Genetic Testing Market was valued at $9.7 Million in 2025 and projected to reach to $14.8 Million by 2030, representing a compound annual growth rate of 8.8%. The Middle East preimplantation genetic testing market is poised for steady growth through 2030, driven by enhanced healthcare infrastructure and rising consumer awareness of genetic screening benefits.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Middle East Preimplantation Genetic Testing Market Trends and Insights
- In the Middle East, rising awareness of genetic disorders, increasing fertility clinic adoption, and growing healthcare investments are driving market penetration.
- The Middle East's market growth is supported by improving regulatory frameworks and enhanced access to assisted reproductive technologies across the region. The Middle East PGT market reflects regional demand for advanced reproductive health solutions, with fertility centers in the Middle East increasingly integrating genetic screening into their service offerings.
- Between 2025 and 2030, the Middle East is expected to see accelerated adoption driven by higher disposable incomes and greater acceptance of genetic testing among Middle Eastern populations.
- The Middle East market trajectory demonstrates strong potential as healthcare infrastructure continues to modernize and patient education initiatives expand..
Key Market Statistics
- CAGR (2025-2030) 8.8% CAGR
- Market Size, 2025 ~USD 9.7 Million
- Forecast, 2030 ~USD 14.8 Million
- Geography Middle East
Middle East Preimplantation Genetic Testing Market Overview
Market Valuation Growth :
The Middle East preimplantation genetic testing market is valued at $9.7 million in 2025 and is projected to reach $14.8 million by 2030, representing a robust 8.8% CAGR over the forecast period.
Rising Genetic Disorder Awareness :
Increasing awareness of genetic disorders among Middle Eastern populations is driving demand for preimplantation genetic testing services, particularly among couples seeking assisted reproductive technologies.
Fertility Clinic Expansion :
Growing adoption of PGT across fertility clinics in the Middle East reflects improved healthcare infrastructure and increased accessibility to advanced reproductive medicine technologies in the region.
Healthcare Investment Surge :
Substantial healthcare investments and improving regulatory frameworks across Middle Eastern countries are creating favorable conditions for market expansion and technology adoption in genetic testing services.
Middle East Preimplantation Genetic Testing Market Dynamics
- Key growth catalysts include increased fertility clinic adoption, supportive regulatory environments, and growing healthcare expenditures across the region.
- The market's 8.8% CAGR reflects strong demand from couples seeking advanced reproductive solutions and genetic disorder prevention. Regional expansion is supported by improving access to fertility services and growing acceptance of assisted reproductive technologies.
- As healthcare systems modernize and regulatory frameworks strengthen, the Middle East is expected to see increased penetration of PGT services.
- Investment in medical facilities and trained professionals will further accelerate market growth, positioning the region as an emerging hub for advanced genetic testing in reproductive medicine..
Related Ecosystem
Advanced Genetic Sequencing
- Polymerase Chain Reaction (PCR)
- Reagents
- Assay Kits
- Bioinformatics
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Agilent Technologies, Inc.
- Qiagen N.V.
- Danaher Corporation
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Key Takeaways
- The Middle East PGT market is valued at $9.7 million in 2025 and will grow to $14.8 million by 2030, representing an 8.8% CAGR.
- The Middle East market growth is driven by increased fertility clinic adoption and rising awareness of genetic screening benefits.
- The Middle East benefits from improving regulatory environments and enhanced healthcare infrastructure supporting reproductive technologies.
- The Middle East demonstrates strong market potential with higher disposable incomes and growing patient acceptance of genetic testing solutions.
Preimplantation Genetic Testing Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | SINGLE GENE DISORDERS (Application) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 10.5% from 2025 to 2030 |
| Largest Segment | PREIMPLANTATION GENETIC SCREENING (Procedure Type) |
| Market Size Base Year (Billions) | ~USD 0.69 (2025) |
| Revenue Forecast (Billions) | ~USD 1.14 (2030) |
| Segments Covered | Product & Service, Procedure Type, Technology, Application, Type, Type Of Cycle, End User |
Middle East Preimplantation Genetic Testing Market Report Segmentation
7 segment dimensions are covered across the global market.
By Product & Service
- Instruments
- Reagents & Consumables
- Software & Services
By Procedure Type
- Preimplantation Genetic Diagnosis
- Preimplantation Genetic Screening
By Technology
- Comparative Genomic Hybridization
- Fluorescence In Situ Hybridization
- Next-Generation Sequencing
- Polymerase Chain Reaction
- Single-Nucleotide Polymorphism
By Application
- Aneuploidy
- Gender Identification
- Hla Typing
- Single Gene Disorders
- Structural Chromosomal Abnormalities
- X-Linked Disorders
By Type
- Deletions
- Duplications
- Inversions
- Translocations
By Type Of Cycle
- Fresh Donor
- Fresh Non-Donor
- Frozen Donor
- Frozen Non-Donor
By End User
- Diagnostic Laboratories
- Fertility Clinics
- Hospitals
- Other End Users
Target Audience
- Fertility Clinic Operators : Clinic owners and managers need market data to assess expansion opportunities, understand competitive positioning, and make informed decisions about PGT service integration in the Middle East.
- Medical Device Manufacturers : PGT equipment and diagnostic solution providers require regional market insights to identify growth opportunities, optimize product offerings, and develop distribution strategies for Middle Eastern markets.
- Healthcare Investors : Investment firms and healthcare funds need comprehensive market analysis to evaluate investment potential, assess regional growth prospects, and identify high-potential opportunities in Middle Eastern reproductive medicine.
- Regulatory and Policy Bodies : Government health agencies and regulatory authorities require market intelligence to develop informed healthcare policies, establish appropriate regulatory frameworks, and support healthcare infrastructure development.
- Healthcare Consultants : Management consulting firms and healthcare advisors need detailed market data to provide strategic recommendations to clients entering or expanding in the Middle East PGT market.
Key Companies in the Middle East Preimplantation Genetic Testing Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| CIMARON LABEL | Pressure-sensitive paper labels,Film and durable labels,Specialty/custom applications, | ||
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Laboratory Products and Biopharma Services,Life Sciences Solutions,Analytical Instruments, |
| AGILENT TECHNOLOGIES, INC. | United States | Public Company | Life Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets, |
| REVVITY | United States | Public Company | Reagents, Assays, and Consumables,Instruments and Detection/Imaging Platforms,Software, Subscriptions, and Informatics, |
| COOPERCOMPANIES | United States | Public Company | Spherical contact lenses,Toric and multifocal contact lenses,Fertility consumables, equipment, and services, |
| ABBOTT | United States | Public Company | Diagnostic Products,Medical Devices,Nutritional Products, |
| TAKARA BIO INC. | Japan | Private Company | Research reagents for genetic and cellular research,Instruments (PCR instruments and cellular analysis devices),In vitro diagnostics (including COVID-19 testing), |
| VITROLIFE | Sweden | Public Company | IVF media and oil,Labware (dishes, pipettes, tubes, VitroTemp, eWitness-related consumables),Cryopreservation solutions, |
CIMARON LABEL
Insufficient information provided to generate description.
THERMO FISHER SCIENTIFIC INC.
Thermo Fisher Scientific Inc. is a United States-based public company founded in 1956 with 125,000 employees. The company is a global leader in serving science, providing laboratory equipment, reagents, and analytical instruments.
AGILENT TECHNOLOGIES, INC.
Agilent Technologies, Inc. is a United States-based public company founded in 1999 with 18,000 employees. The company provides life sciences, diagnostics, and applied chemical markets with instruments and software.
REVVITY
Revvity is a United States-based public company founded in 1937 with 11,000 employees. The company provides analytical technologies and solutions for research, diagnostics, and applied markets.
COOPERCOMPANIES
CooperCompanies is a United States-based public company founded in 1958 with 15,000 employees. The company operates in the medical device sector, primarily focused on contact lenses and eye care products.
ABBOTT
Abbott is a United States-based public company founded in 1888 with 115,000 employees. The company is a diversified healthcare manufacturer producing pharmaceuticals, diagnostics, nutritional products, and medical devices.
TAKARA BIO INC.
Takara Bio Inc. is a Japan-based private company founded in 2002 with 1,779 employees. The company specializes in biotechnology research and development.
VITROLIFE
Vitrolife is a Sweden-based public company founded in 1989 with 1,103 employees. The company develops and manufactures products for assisted reproduction and embryo culture.
Countries within Middle East - compare and drill down
| Country | 2025 size (native) |
|---|---|
| UAE | USD 2.6 Million |
| Kingdom Of Saudi Arabia | USD 4 Million |
| Rest Of GCC Countries | USD 1.7 Million |
| GCC Countries | USD 1.2 Million |
| Rest Of Middle East | USD 0.93 Million |
Country market size visualization
Reasons to Buy this Report
- Regional Market Sizing : Obtain precise market valuation data for the Middle East PGT market, including country-level breakdowns for UAE, Saudi Arabia, and GCC nations to inform regional expansion strategies.
- Growth Trajectory Analysis : Understand the 8.8% CAGR growth dynamics specific to the Middle East, enabling accurate forecasting and investment planning through 2030 with regional context.
- Competitive Landscape Intelligence : Gain insights into fertility clinic adoption rates, regulatory environments, and healthcare investment patterns unique to Middle Eastern markets to identify competitive advantages.
- Market Entry Strategy : Leverage country-specific data for UAE, Saudi Arabia, and other GCC nations to develop targeted market entry strategies and localized business plans for the region.
- Investment Decision Support : Access comprehensive market analysis to support investment decisions, partnership opportunities, and resource allocation across Middle Eastern fertility and genetic testing sectors.
Frequently asked questions
What is the current market size of PGT in the Middle East?
The Middle East preimplantation genetic testing market was valued at $9.7 million in 2025.
What is the projected market size for PGT in the Middle East by 2030?
The Middle East PGT market is forecast to reach $14.8 million by 2030.
What is the growth rate of the PGT market in the Middle East?
The Middle East PGT market is expected to grow at a compound annual growth rate (CAGR) of 8.8% from 2025 to 2030.
What factors are driving PGT market growth in the Middle East?
The Middle East market is driven by rising awareness of genetic disorders, increased fertility clinic adoption, growing healthcare investments, and improving regulatory frameworks.
How does the Middle East PGT market compare to global growth?
The Middle East PGT market grows at 8.8% CAGR, slightly below the global average of 10.5%, reflecting regional market maturation and adoption patterns.
RESEARCH METHODOLOGY
This research extensively used secondary sources, directories, and databases to gather valuable information for analyzing the global preimplantation genetic testing market. In-depth interviews were conducted with various primary respondents, including key industry players, subject-matter experts (SMEs), C-level executives, and industry consultants, to obtain and verify important qualitative and quantitative data and evaluate the market’s growth prospects. The global market size estimated through secondary research was cross-checked with inputs from primary research to determine the final market size.
Secondary Research
Secondary research was mainly used to gather information for the detailed technical, market, and commercial analysis of the preimplantation genetic testing market. The secondary sources for this study include the World Health Organization (WHO), World Bank, Human Fertilization and Embryology Authority (HFEA), International Federation of Fertility Societies (IFFS), American Society for Reproductive Medicine (ASRM), Australia and New Zealand Assisted Reproduction Database (ANZARD), Centers for Disease Control and Prevention (CDC), Society for Assisted Reproductive Technology (SART), National Health Service (NHS), Indian Fertility Society (IFS), British Fertility Society (BFS), European Society of Human Reproduction and Embryology (ESHRE), Association for Fertility and Reproductive Health (AFRH), German Society of Reproductive Medicine (DGRM), Canadian Fertility & Andrology Society (CFAS), Indian Society for the Study of Reproduction and Fertility (ISSRF), Spanish Fertility Society (Sociedad Española de Fertilidad-SEF), Japan Society for Reproductive Medicine, National Registry of Assisted Reproductive Technology and Surrogacy Registry, Journal of Human Reproductive Sciences, American Congress of Obstetricians and Gynecologists (ACOG), European Society of Human Genetics (ESHG); ACS Journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations.
Secondary data was collected and analyzed to determine the overall size of the global preimplantation genetic testing market, which was then validated through primary research. These sources also provided key information about major players, market classification, and segmentation based on industry trends, regional and country-level markets, market developments, and technological perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The top-down and bottom-up approaches were used to estimate & validate the total size of the preimplantation genetic testing market. These methods were also used extensively to estimate the size of various market segments.
Data Triangulation
After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.
Market Definition
Preimplantation genetic testing (PGT) examines embryos during in vitro fertilization (IVF) before possible transfer to a woman's uterus. This is done to test a range of genetic problems that can cause implantation failure, miscarriage, and birth defects in a resulting child.
Preimplantation genetic testing refers to the three types of tests that may be performed on embryos during IVF:
- Preimplantation genetic screening for abnormal chromosome number (PGT-A)
- Preimplantation genetic testing for monogenic (individual) disease (PGT-M)
- Preimplantation genetic testing structural rearrangement (PGT-SR) for known chromosomal misarrangements such as inversion and translocation.
The study offers an in-depth analysis of the preimplantation genetic testing market, examining contemporary market trends and developments, as well as its potential growth from 2025 to 2030. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key preimplantation genetic testing product and service providers.
Stakeholders
- Contract research organizations (CROs)
- Contract development and manufacturing organizations (CDMOs)
- In vitro fertilization (IVF) centers and fertility clinics
- Life science companies
- Fertility clinics
- Academic & research institutes
- Private research institutes
- Venture capitalists & investors
- Market research & consulting firms
- Government associations
- Medical institutions & universities
- Hospitals & clinics
Report Objectives
- To define, describe, and forecast the preimplantation genetic testing market based on procedure type, technology, product & service, application, type of cycle, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall preimplantation genetic testing market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To strategically profile the key players in the preimplantation genetic testing market and comprehensively analyze their core competencies and market rankings
- To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the preimplantation genetic testing market
- To benchmark players within the preimplantation genetic testing market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy
Get the Full Preimplantation Genetic Testing Market Report
Full forecast, segment splits, and company analysis for all Preimplantation Genetic Testing Market.
- Canada Preimplantation Genetic Testing Market
- US Preimplantation Genetic Testing Market
- Germany Preimplantation Genetic Testing Market
- UK Preimplantation Genetic Testing Market
- France Preimplantation Genetic Testing Market
- Italy Preimplantation Genetic Testing Market
- Spain Preimplantation Genetic Testing Market
- China Preimplantation Genetic Testing Market
- Japan Preimplantation Genetic Testing Market
- India Preimplantation Genetic Testing Market
- Australia Preimplantation Genetic Testing Market
- South Korea Preimplantation Genetic Testing Market
- Brazil Preimplantation Genetic Testing Market
- Mexico Preimplantation Genetic Testing Market
- UAE Preimplantation Genetic Testing Market
- Rest Of Europe Preimplantation Genetic Testing Market
- Rest Of Asia Pacific Preimplantation Genetic Testing Market
- Rest Of Latin America Preimplantation Genetic Testing Market
- Kingdom Of Saudi Arabia Preimplantation Genetic Testing Market
- Rest Of GCC Countries Preimplantation Genetic Testing Market
- GCC Countries Preimplantation Genetic Testing Market
- Rest Of Middle East Preimplantation Genetic Testing Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
